Navigation Links
Prix Galien USA Announces 2008 Final Candidates
Date:8/12/2008

Honorees for best pharmaceutical agent and best biotechnology product to be recognized at Sept. 24 gala ceremony

NEW YORK, Aug. 12 /PRNewswire-USNewswire/ -- The Prix Galien USA 2008 (http://www.prix-galien-usa.com) will recognize innovative biopharmaceutical drugs and devices that have made a deep impact on the quality of human life in ways that range from providing treatment for cancer and HIV/AIDS to hypertension and chronic pain. Charlie Rose will again emcee the awards ceremony on September 24, 2008, to be held at the American Museum of Natural History in New York.

The final candidates for the Prix Galien USA 2008 awards are:

-- Actelion Ltd. - Ventavis(R) (Iloprost)

-- Alexion Pharmaceuticals - Soliris(TM)

-- BioMarin Pharmaceutical Inc. - Nagalzyme(R)

-- Bristol-Myers Squibb - Sprycel(R)

-- Boehringer Ingelheim - Aptivus(R) and Spiriva(R)

-- Celgene Corporation - Revlimid(R)

-- CV Therapeutics Inc. - Ranexa(R) (ranolazine)

-- Elan Corporation - Prialt(R) (ziconotide intrathecal infusion)

-- Eli Lilly Company - Evista(R) raloxifene HCI

-- Genzyme Corporation - Myozyme(R)

-- GlaxoSmithKline - Tykerb(TM) (lapatinib) and Altabax(TM) (retapamulin ointment)

-- Merck & Co. - Isentress(R) (raltegravir)

-- Novartis AG - Exjade(R) (deferasirox) and Tekturna(R)

-- Nycomed - Omnaris

-- Pfizer Inc. - Selzentry(TM)

-- Roche Laboratories Inc. - Boniva(R)

-- sanofi-aventis - Lovenox(R)

-- Sanofi Pasteur - H5N1 influenza virus vaccine

-- Sucampo Pharmaceuticals, Inc. - Amitiza(R)

-- Wyeth - Infuse/InductOs (rh BMP-2 dibotermin alfa) Torisel (temsirolimus) Injection.

"Nominees for the Prix Galien USA stand apart from other drugs in the marketplace for the amount of research and level of skill that was invested to develop these innovative medicines that improve lives," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal.

At the awards ceremony The Population Council and Sheldon Segal, distinguished scientist at the organization, will receive the Prix Galien USA 2008 Pro Bono Humanum Award along with other members of the coalition -- Wyeth, Dow Corning and the late Judah Folkman of Harvard University -- that made possible the development and distribution of implantable hormone delivery systems that are used for birth control and family planning purposes by more than 8 million women worldwide.

The Prix Galien USA Awards (http://www.prix-galien-usa.com) committee of 11, including 7 Nobel Laureates, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines that improve the human condition, and is considered the industry's highest accolade for pharmaceutical research and development -- equivalent to the Nobel Prize.


'/>"/>
SOURCE Prix Galien USA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
2. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
3. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
4. Telik Announces Financial Results For 2008 Second Quarter
5. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
6. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Biologic Products Announces Second Quarter 2008 Results Conference Call
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA ... dose escalation and expansion clinical trial for its lead drug candidate, AC0010, at ... of the trial was to determine the safety, antitumor activity, and recommended phase ...
(Date:12/7/2016)... LANSING, Mich. , Dec. 7, 2016 ... it has named Dr. Dan Kephart as ... the company. Kephart will assume his responsibilities at Neogen ... research and development director for the agribusiness unit of ... food safety development at Life Technologies. His extensive industry ...
(Date:12/7/2016)... 2016  Nordion, a standalone business of Sterigenics ... today,s award by the United States Department of ... the Phase II cooperative agreement funding to GA ... University of Missouri Research Reactor Center (MURR ® ... establishment of a new, reliable supply of molybdenum ...
Breaking Biology Technology:
(Date:11/22/2016)... , November 22, 2016 According to the new ... Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function ... by MarketsandMarkets, the market is expected to grow from USD 10.74 Billion ... of 16.79% between 2016 and 2022. Continue ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):